Effective part of podophyllum hexandrum and application of effective part in preparation of medicine for treating rheumatoid arthritis
Oral preparation prepared by the dichloromethane extraction site of Taoer's seven rhizomes solved the toxic side effects and slow onset of the existing rheumatoid arthritis treatment, significantly inhibited TNF-α and JAK1, alleviated the symptoms of arthritis and Injury, it demonstrates efficient and low toxic anti-RA effects.
Patent Information
- Application Number
- CN202411278732.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-15
AI Technical Summary
The existing rheumatoid arthritis treatment drugs have severe toxic and side effects, slow onset and difficult to curb bone destruction and complications. The clinical compliance rate is low, and there is a lack of novel anti-RA drugs with high efficiency, low toxicity and strong selectivity.
The dichloromethane extraction site of Sinopodophyllum hexandrum rhizome was used as the effective site. The extract obtained by reflux extraction and extraction was performed for extraction. Combined with petroleum ether and dichloromethane extraction, it was prepared to significantly inhibit TNF-α and JAK1 active oral preparation for the treatment of rheumatoid arthritis.
It significantly inhibited the proliferation of fiber-like synovial cells in rats induced by TNF-α, alleviated the degree of foot swelling and joint damage in the rat RA model induced by complete Freund's adjuvant, decreased the level of inflammatory factors, and showed efficient anti-RA activity.
Smart Images

Figure CN118948921A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine and relates to an effective part of Psoralea corylifolia and application thereof in preparing a medicine for treating rheumatoid arthritis. Background Art
[0002] Rheumatoid arthritis (RA) is a systemic autoimmune disease with erosive arthritis as the main clinical manifestation. It is characterized by chronic inflammation of the synovial membrane and progressive destruction of the joints, often manifested as joint swelling, pain, and difficulty in flexion and extension. [1,2] At present, it is believed that the cause of RA is related to genetics, infection, sex hormone levels, environment and other factors. Its basic pathological changes are chronic synovitis and pannus, which gradually lead to joint cartilage and bone destruction, and eventually lead to joint deformity and loss of function. [3] RA is most common in people aged 25 to 50. Untreated RA has a high disability rate and can be accompanied by extra-articular damage, affecting multiple organs such as the heart, lungs, and kidneys, seriously affecting the patient's quality of life. The global incidence of RA is about 0.5% to 1%. The direct cost of RA treatment and the indirect economic losses caused by loss of labor force are huge each year. [2] .
[0003] At present, the drugs used to treat RA mainly include hormone drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), but they all have certain shortcomings. For example, hormone drugs have great toxic side effects and can only be used as short-term treatment drugs; NSAIDs can relieve symptoms and take effect quickly, but cannot control the progression of the disease; DMARDs can delay and control the progression of the disease to a certain extent, but they take effect slowly and have risks such as bone marrow suppression and abnormal liver function. [4] Low clinical achievement rate, frequent drug side effects, uncontrollable bone destruction and complications are still objective treatment difficulties. [5] In recent years, researchers have carried out a lot of work on the anti-RA effects of traditional Chinese medicine, including antibacterial, anti-inflammatory, analgesic and immunomodulatory effects. A variety of RA treatment drugs have been developed from traditional anti-rheumatic and anti-inflammatory Chinese medicines, such as Tripterygium wilfordii polyglycosides tablets, Sinomenine injection and white peony total glucosides capsules. [6-8] The above drugs can relieve the clinical symptoms of RA patients and curb the progression of the disease to a certain extent. At present, there is still an urgent need for good drugs with high-quality evidence-based evidence in the clinic. It is of great clinical significance to find new anti-RA drugs with high efficiency, low toxicity and strong selectivity from traditional Chinese medicine or ethnic medicine.
[0004] Sinopodophyllum hexandrum (Royle) Ying is a perennial herbaceous plant of the genus Sinopodophyllum in the Berberidaceae family. It is mainly distributed in Tibet, Yunnan, Sichuan and other places in China, and also in India, Pakistan, Afghanistan, Bhutan and Nepal. [9] Taoerqi was first recorded in the Shennong's Herbal Classic as "Ghost Morus" and is a traditional Tibetan medicinal material. The main chemical components of Taoerqi include flavonoids [10-12] , lignans [13,14] , small amounts of sterols
[15] and phenolic acid components
[16] It has multiple biological activities such as anti-tumor, anti-virus, anti-inflammatory, antibacterial and insecticidal [17,18] .
[0005] References
[0006] [1]Smolen JS, Aletaha D, Mclnnes L. Rheumatoid arthritis[J]. Lancet, 2016, 388(10055):2023-2038.
[0007] [2] Chinese Society of Rheumatology. 2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis[J]. Chinese Journal of Internal Medicine, 2018, 57(4): 242-251.
[0008] [3]McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis[J]. New England Journal of Medicine, 2011, 365(23):2205-2219.
[0009] [4] Geng Yan, Xie Xi, Wang Yu, Jiang Dexun, Zhang Wen, Zhang Zhuoli, Zhao Yan, on behalf of the Chinese Society of Rheumatology. Standards for the diagnosis and treatment of rheumatoid arthritis[J]. Chinese Journal of Internal Medicine, 2022, 61(1): 51-59.
[0010] [5] Zhang Xiaoxiao, Lu Yao, Hou Wei, Zhu Mingjun, Tang Xudong, Xiong Lei, Jiang Quan, Zeng Xianyu, Li Haisong, Zhao Ruihua, Wang Guochen, Zhang Boli. List of clinical requirements for the development of new Chinese medicines (first batch)[J]. Journal of Traditional Chinese Medicine, 2024, 65(1):17-25.
[0011] [6] Feng Z, Fu L, Wang J, Zhu Y, He X, Zhou L, Zhou
[0012] [7] Duan D, Wang Y, Pan D, Jin X, Yan Y, Song P, Wang L, Xiao J, Wang Z, Wang
[0013] [8]Qu B, Wang XL, Zheng DC, Mai CT, Liu ZQ, Zhou H, Xie Y. Noveltreatment for refractory rheumatoid arthritis with total glucosides of paeonyand nobiletin codelivered in a self-nanoemulsifying drug delivery system[J]. Acta Pharmacologica Sinica, 2022,43:2094-2108.
[0014] [9] Fu Liguo. Red Data Book of Chinese Plants - Rare and Endangered Plants (Volume 1)[M]. Beijing: Science Press, 1992: 691.
[0015]
[10] Sun Yanjun, Zhou Wei, Chen Hong, Li Zhanlin, Hua Huiming. Isolation and identification of flavonoids from Psoralea corylifolia[J]. Journal of Shenyang Pharmaceutical University, 2012, 29(3): 185-189.
[0016]
[11] Sun YJ, Chen HJ, Xue GM, Chen H, Zhang YL, Li M, Du K, Wang JM, FengW S. Two new flavonoid glucosides from the fruits of Sinopodophyllum hexandrum[J]. Natural Product Research, 2021, 35: 2164-2169.
[0017]
[12] Sun Y,Chen H,Wang J,Gao M,Zhao C,Han R,Chen H,Li M,Xue G,FengW.Sixteen new prenylated flavonoids from the fruit of Sinopodophyllumhexandrum[J]. Molecules,2019,24:3196.
[0018]
[13] Jackson DE, Dewick P M.Aryltetralin lignans from Podophyllumhexandrum and Podophyllum peltatum[J].Phytochemistry,1984,23:1147-1152.
[0019]
[14] Sun YJ,Li ZL,Chen H,Liu XQ,Zhou W,Hua H M.Three new cytotoxicaryltetralin lignans from Sinopodophyllum emodi[J].Bioorganic&MedicinalChemistry Letters, 2011,21:3794-3797.
[0020]
[15] Sun Yanjun, Li Zhanlin, Chen Hong, Zhou Wei, Hua Huiming. Study on chemical components of Psoralea corylifolia[J]. Chinese Medicinal Materials, 2012, 35:1607-1609.
[0021]
[16] Sun Yanjun, Zhou Wei, Chen Hong, Li Zhanlin, Hua Huiming. Study on phenolic components in Psoralea corylifolia[J]. Chinese Medicinal Materials, 2012, 43(2): 226-229.
[0022]
[17] Yan Shuting, Fan Hao, Li Ruolan, Guo Yanli, Liu Qiao, Gao Feng, Ou Li, Chen Lin, Li Min, Wei Peifeng, Zhang Lei. Research progress on chemical components and pharmacological effects of Psoralea corylifolia[J]. Chinese Wild Plant Resources, 2020, 39(7): 43-50.
[0023]
[18] Anand U,Biswas P,Kumar V,Ray D,Ray P,Loake V IP,Kandimalla R,Chaudhary A,Singh B,Routhu NK,Chen ZS, J,Dey A.Podophyllum hexandrum and its active constituents:Novel radioprotectants[J]. Biomedicine&Pharmacotherapy, 2022,146:112555-112566. Summary of the invention
[0024] The inventors used a TNF-α-induced rat fibroblast-like synoviocyte (FLS cell) proliferation model to screen the in vitro anti-RA (rheumatoid arthritis) activity of different extraction parts of the rhizome ethanol extract of Sinopodophyllum hexandrum (Royle) Ying. The results showed that the dichloromethane extract of Sinopodophyllum hexandrum (Royle) Ying (denoted as SHD Fr) had a significant inhibitory effect on FLS cells (IC 50 The value was 8.45 μg / mL), while the other extraction parts IC 50 The values were all greater than 200 μg / mL, which preliminarily indicated that SHD Fr had anti-RA activity in vitro. In the rat RA model induced by complete Freund's adjuvant (CFA), oral administration of SHD Fr could reduce the degree of foot swelling and joint damage in RA rats in a dose-dependent manner, and inhibit the levels of multiple inflammatory factors in the blood and synovial tissue.
[0025] The purpose of the present invention is to provide an effective fraction of Psoralea corylifolia and its application in preparing a medicine for treating rheumatoid arthritis.
[0026] The objective of the present invention is achieved through the following technical solutions:
[0027] A kind of effective part of Psoralea corylifolia, which is the dichloromethane extraction part of the alcohol extract of Psoralea corylifolia rhizome.
[0028] The alcohol extract of the rhizome of Psoralea corylifolia is prepared by taking the dried rhizome of Psoralea corylifolia as raw material, taking 75% to 95% ethanol as extraction solvent, performing reflux extraction and filtering to obtain an extract, and recovering the extract until there is no alcohol taste to obtain an extract.
[0029] As the preferred technical scheme described in the present invention, an effective part of Psoralea corylifolia is prepared from dried Psoralea corylifolia rhizomes as raw materials, 75% to 95% ethanol as extraction solvent, reflux extraction, filtration to obtain an extract, the extract is recovered until there is no alcohol taste to obtain an extract, the extract is suspended in water, first extracted with petroleum ether, then extracted with dichloromethane, and the dichloromethane extract is concentrated to dryness to obtain a dichloromethane extraction part.
[0030] Preferably, the effective part of Psoralea corylifolia is prepared by the following method: using dried Psoralea corylifolia rhizome as raw material, crushing, adding 75% to 95% ethanol at a solid-liquid ratio of 1:10kg / L for reflux extraction, adding 75% to 95% ethanol at a solid-liquid ratio of 1:8kg / L for reflux extraction twice for the filter residue; after each reflux extraction, filtering, collecting the extract, and combining the extracts; recovering the extract until there is no alcohol taste to obtain an extract, suspending the extract in water, extracting with petroleum ether for 3 times, extracting with dichloromethane for 3 times in sequence, and concentrating the dichloromethane extract to dryness to obtain the dichloromethane extraction part, which is the effective part of Psoralea corylifolia.
[0031] Preferably, the extraction solvent is 95% ethanol.
[0032] Preferably, the time of each reflux extraction is 1 hour.
[0033] Another object of the present invention is to provide the use of the effective fraction of Psoralea corylifolia in the preparation of a drug for treating rheumatoid arthritis.
[0034] Preferably, the application is the application of the effective fraction of Herba Cibotii in the preparation of a drug for treating rheumatoid arthritis by inhibiting TNF-α and JAK1.
[0035] Another object of the present invention is to provide a medicine for treating rheumatoid arthritis, comprising an effective therapeutic dose of the effective part of Psoralea corylifolia and pharmaceutically acceptable excipients.
[0036] The dosage form of the medicine is an oral preparation.
[0037] Preferably, the oral preparation is any one of tablets, capsules, granules, suspensions, dripping pills, pills, and oral liquid preparations.
[0038] The tablets are common oral tablets, dispersible tablets, orally disintegrating tablets or sustained-release tablets. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 The in vitro anti-RA activity of different extracts of Psoralea corylifolia; A is the effect of different extracts of Psoralea corylifolia on TNF-α-induced rat FLS cell proliferation; B is the inhibitory IC of SHD Fr on TNF-α-induced rat FLS proliferation 50 Compared with the blank control group, *** p<0.001; compared with the model group, ## p<0.01, ## p<0.001.
[0040] Figure 2 The in vivo efficacy of SHD Fr against CFA-induced RA in rats; A is the dynamic curve of rat foot thickness at different time points; B is the actual photograph of the sole, knee joint HE staining, and knee joint safranin-fast green staining on the last day of drug administration.
[0041] Figure 3 The effect of SHD Fr on the contents of TNF-α(A), IL-6(B), and IL-1β(C) in synovial tissue of CFA-induced RA rat model; compared with the blank control group, *** p<0.001; compared with the model group, # p<0.05, ## p<0.01, ## p<0.001.
[0042] Figure 4 The effect of SHD Fr on the levels of TNF-α(A), IL-6(B), and IL-1β(C) in the blood of CFA-induced RA rat model; compared with the blank control group, *** p<0.001; compared with the model group, # p<0.05, ## p<0.01, ## p<0.001.
[0043] Figure 5 The effects of SHD Fr on TNF-α and JAK1 downstream signaling pathways in synovial tissue; A is the effect of SHD Fr on the expression of proteins related to the TNF-α downstream signaling pathway; B is the effect of SHD Fr on the expression of proteins related to the JAK1 downstream signaling pathway; C is the effect of SHD Fr on the levels of NF-κB and NFATc1 in synovial tissue measured by immunohistofluorescence method. DETAILED DESCRIPTION
[0044] The technical solution of the present invention is further described below through specific implementation methods.
[0045] Example 1
[0046] Extraction and extraction of Taoerqi medicinal materials
[0047] 20 kg of dried stems of Psoralea corylifolia were taken, crushed and passed through a No. 2 sieve, 95% ethanol was added at a solid-liquid ratio of 1:10 kg / L, heated under reflux for extraction for 1 hour, cooled to room temperature, filtered through gauze, and the extract was collected; 95% ethanol was added to the filter residue at a solid-liquid ratio of 1:8 kg / L, heated under reflux for extraction twice, each time for 1 hour, filtered through gauze, and the extract was collected; the extracts were combined, and the ethanol was recovered by rotary evaporation until there was no alcohol taste and almost dry, to obtain an ethanol extract (SHE Ext); SHE Ext was suspended in warm water to obtain an extract dispersion, and the extract was repeatedly extracted 3 times with an equal volume of petroleum ether, the petroleum ether extracts were combined, and concentrated to dryness to obtain a petroleum ether extraction fraction (recorded as SHP Fr, 209 g); the mother liquor was extracted 3 times with an equal volume of dichloromethane, the dichloromethane extracts were combined, and concentrated to dryness to obtain a dichloromethane extraction fraction (recorded as SHD The mother liquor was extracted three times with an equal volume of water-saturated n-butanol, and the n-butanol extracts were combined and concentrated to dryness to obtain the n-butanol extraction fraction (recorded as SHB Fr, 511 g); the remaining mother liquor was concentrated to dryness to obtain the water layer (recorded as SHW Layer, 325 g).
[0048] Example 2
[0049] Study on the anti-RA activity of different extracts of Psoralea corylifolia in vivo and in vitro
[0050] In order to explore the material basis of the anti-rheumatic pain and anti-RA efficacy of Psoralea corylifolia L., the inventors used a TNF-α-induced rat synovial fibroblast (FLS cell) proliferation model to perform in vitro anti-RA screening on different extraction parts (SHPFr, SHD Fr, SHB Fr) of Psoralea corylifolia L. obtained in Example 1.
[0051] Cell culture: Take out the cryopreserved tube containing FLS cells from liquid nitrogen and revive the cells; inoculate the cells into DMEM culture medium containing 10% FBS, 1% streptomycin and penicillin, so that the cells are evenly spread on the bottom of the culture bottle, put it in a cell culture incubator, and culture it at 37°C, 5% CO2, and 95% relative humidity. Select FLS cells that have grown well and have been passed on for 3 to 6 generations for experiments.
[0052] Experimental grouping, drug administration scheme and establishment of cell model: FLS cells in the logarithmic growth phase were collected and cultured at 2×10 5cells / well were plated in a 6-well plate, and 2 mL was inoculated in each well. When the cells grew to 70%-80%, a blank control group, a model group, and different concentrations of drug administration groups (SHP Fr, SHD Fr, SHB Fr, 10, 20, 40, 80, 100 μg / mL) were set up. The blank control group was replaced with fresh culture medium, and each well of the other groups was replaced with a culture medium containing TNF-α (final concentration of 20 ng / mL) and cultured for 12 h; the blank control group continued to be replaced with fresh culture medium, the model group was replaced with a culture medium containing TNF-α (final concentration of 20 ng / mL), and the drug administration group was replaced with a culture medium containing the corresponding concentration of the drug to be tested (containing TNF-α final concentration of 20 ng / mL) and continued to be cultured for 24 h. The optical density D(λ) value of each group of cells was detected using the MTS Cell Proliferation Colorimetric Assay Kit according to the instructions, and the inhibition rate of the drug on the cells was calculated.
[0053] The results showed that SHD Fr could inhibit the proliferation of FLS cells in a concentration-dependent manner, while other extracts had no such activity. 50 The values were all greater than 200 μg / mL ( Figure 1 A) IC of SHD Fr against TNF-α-induced FLS cell proliferation 50 8.45 μg / mL ( Figure 1 B). The above results indicate that the dichloromethane extract of the stem of Psoralea corylifolia has strong anti-RA activity in vitro.
[0054] Example 3
[0055] The complete Freund's adjuvant (CFA)-induced RA model in rats was used to evaluate the anti-RA activity of SHD Fr in vivo.
[0056] Model establishment: After the rats were anesthetized with isoflurane, the area around their right paws was disinfected. The normal control group rats were injected with normal saline (0.1 mL / rat), and the rats in the other groups were injected with 0.1 mL CFA in the right paws to induce inflammation and develop into adjuvant-induced arthritis (AIA). The day of modeling was counted as day 0.
[0057] Experimental grouping and dosing regimen: The rats were randomly divided into blank control group, model group, positive control group (Tofacitinib, 15 mg / kg), and different dose dosing groups, with 10 animals in each group, male, 8-10 weeks old. The blank control group did not receive any treatment. The model group and the drug group were given normal saline by gavage 11 days after modeling. The rats in the model group were given tofacitinib (15 mg / kg) by gavage. The rats in the drug group were given drugs of corresponding concentrations (SHD Fr: 25 and 50 mg / kg) by gavage. The drugs were administered continuously for 10 days. The rats were killed on the 21st day and the relevant experiments were carried out.
[0058] Determination of ankle or wrist swelling of AIA rats: After modeling, the degree of redness and swelling of the ankle joints, metatarsophalangeal joints and interphalangeal joints of the hind limbs of AIA rats was measured every 3 days using a vernier caliper to observe the inhibitory effect of the drug on the swelling of the ankle or wrist joints of AIA rats.
[0059] Analysis of joint tissues of AIA rats by staining method: Rats were killed by cervical dislocation on the 21st day, and the ankle joints were removed, fixed with 4% paraformaldehyde, decalcified with 10% EDTA, routinely dehydrated, embedded in paraffin, sectioned, stained with HE and safranin-fast green, and X-rayed.
[0060] ELISA method was used to determine the levels of TNF-α, IL-6 and IL-1β in synovial tissue and blood.
[0061] Results Figure 2-Figure 4 , showing that oral administration of SHD Fr (25, 50 mg / kg) can dose-dependently reduce CFA-induced paw swelling in rats ( Figure 2 A). Pathological results showed that in the normal group, cells were arranged evenly, cell nuclei were clearly visible, coloring was even, and no synovial thickening and angiogenesis were observed; in the model group, cells were arranged in a disorderly manner, synovial membrane was severely hyperplastic, some cell nuclei were necrotic, coloring was uneven, defects and pannus formation were visible; compared with the model group, SHD Fr had mild hyperplasia, mild angiogenesis and some inflammatory cell infiltration ( Figure 2 B). In addition, SHD Fr can significantly reduce the levels of multiple inflammatory factors such as TNF-α, IL-6, and IL-1β in synovial tissue and blood ( Figure 3 and Figure 4 The above results indicate that the dichloromethane extract of the stem of Psoralea corylifolia (SHD Fr) has a strong anti-RA activity in vivo and is an effective extract of Psoralea corylifolia against RA.
[0062] Example 4
[0063] Study on the chemical components of dichloromethane extraction fraction of Herba Psoraleae sutchuenensis (SHD Fr)
[0064] High-resolution mass spectrometry (AB Sciex TripleTOF TM 5600 + The samples treated with SHD Fr were measured using UHPLC-QTOF-MS / MS information-dependent acquisition (IDA) and dynamic background subtraction (DBS). The fragmentation patterns of different types of compounds were analyzed by combining literature data, mass spectrometry databases (mzCloud, MoNA, Metlin, etc.) and mass spectrometry data of separated compounds. Fifty-six chemical components with relatively high contents in SHD Fr were identified, which were mainly flavonoids and lignans, and a small amount of phenolic acid components (the main chemical components are shown in Table 1).
[0065] Study on the anti-RA target of active ingredients in SHD Fr
[0066] Prediction of the targets of the main active ingredients of SHD Fr based on network pharmacology
[0067] Prenylated flavonoids from SHD Fr as potential targets for the treatment of RA
[0068] The prenylated flavonoid component structures obtained by mass spectrometry qualitative analysis were imported into the Swiss TargetPrediction (http: / / www.swisstargetprediction.ch / ) database to obtain their targets, and a total of 173 targets were obtained after deduplication. Using "rheumatoid arthritis, RA" as the keyword, Genecards (https: / / www.genecards.org / ), DrugBank (https: / / www.drugbank.ca / ), GeneNCBI database (https: / / www.ncbi.nlm.nih.gov / gene), and Therapeutic Target Database (https: / / db.idrblab.nttt) were searched, and the RA target database (abbreviated as "RA target") was obtained by collecting and collating the search results and removing duplicates, and a total of 6051 targets were obtained. The active ingredient targets of Psoralea cochinchinensis and RA targets were imported into VENNY2.1 (https: / / bioinfogp.cnb.csic.es / tools / venny / ) to obtain drug-disease intersection targets. After deduplication, the potential targets of Psoralea cochinchinensis for the treatment of rheumatoid arthritis were obtained. They were mapped with the potential targets of the above-mentioned compounds to obtain 113 potential targets of Psoralea cochinchinensis isopentenyl flavonoid components for the treatment of rheumatoid arthritis. The above-mentioned compound-disease common targets were entered into the STRING (https: / / string-db.org / ) database for retrieval, the protein type was set to "Homosapiens", the minimum interaction threshold was set to 0.4, the PPI network of protein interactions was constructed, and it was imported into the Cytoscape software to draw a protein interaction network diagram, and the size and color of the network nodes were set. The size, color and depth of the nodes represent the degree value. The results show that the top five target proteins are TP53, AKT1, TNF-α, SRC and JAK1, indicating that these proteins play an important role in the PPI network. The prenylated flavonoids in Psoralea corylifolia may have a therapeutic effect on RA through these targets.
[0069] Arylnaphthalene lignans from SHD Fr are potential targets for the treatment of RA
[0070] The structures of the qualitatively obtained aromatic naphthyl lignan compounds were imported into the Swiss Target Prediction (http: / / www.swisstarget prediction.ch / ) database to obtain their targets, and a total of 590 targets were obtained after deduplication. The rest of the methods were the same as above. After deduplication, the potential targets of Peach Seven for the treatment of rheumatoid arthritis were obtained. They were mapped with the potential targets of the above compounds to obtain 349 potential targets of Peach Seven flavonoid components for the treatment of rheumatoid arthritis. The above compound-disease common targets were entered into the STRING (https: / / string-db.org / ) database for retrieval, the protein type was set to "Homo sapiens", the minimum interaction threshold was 0.4, the PPI network of protein interaction was constructed, and it was imported into the Cytoscape software to draw a protein interaction network diagram, and the size and color of the network nodes were set. The size, color and depth of the nodes represent the degree value. The results show that the top five target proteins are TNF-α, GAPDH, TP53, TLR4 and SRC, indicating that these proteins play an important role in the PPI network. The aromatic naphthyl lignan compounds in Psoralea corylifolia may have a therapeutic effect on RA through these targets.
[0071] A practical study on the inhibitory effect of SHD Fr on predicted targets
[0072] The screened targets (TP53, AKT1, TLR4, TNF-α, JAK1, GAPDH, SRC) were tested.
[0073] Drug preparation: DMSO was used as a solvent to prepare a SHD Fr stock solution with a concentration of 10 mg / mL, and the SHD Fr stock solution was diluted with DMEM medium containing 10% FBS to obtain drug-containing culture media with different concentrations (the final concentration of SHD Fr was 0.1, 0.5, 1, 10, 25, 50, 150, 200, 300 μg / mL).
[0074] Construction of HEK293 cell lines overexpressing TP53, TLR4, TNF-α, and GAPDH: HEK293 cells were cultured in DMEM medium containing 10% FBS to a confluence of 70-80%. Using the above protein expression plasmids (TP53: 5'-GUAGAUUACCACUGGAGUCdTdT-3'; TLR4: 5'-CCACCAUCUUCACCAACUAdTdT-3'; TNF-α: 5'-UAAAGCCGAUUUGAGAUUCdTdT-3'; GAPDH: 5'-CUUGAGGCUGUUGUCAUACd TdT-3') and reporter gene plasmids, the plasmids and transfection reagents were mixed in serum-free medium. The mixture contained 2 μg of protein plasmids and 2 μg of reporter gene plasmids. The transfection mixture was added to the cell culture plate, gently shaken evenly, and incubated at 37°C in an incubator for 4 to 6 hours; then, it was replaced with a drug-containing medium containing 10% FBS and continued to be cultured for 24 to 48 hours. Collect the cells and lyse the cells using lysis buffer, and collect the supernatant. According to the instructions of the luciferase detection kit, the luciferase detection reagent was added to the sample. Finally, the luciferase activity was detected using a fluorescence or luminescence detector and the relative fluorescence units (RLU) were recorded. The background fluorescence of the untransfected control was subtracted from the detection data. The fluorescence units of the samples were normalized to the internal reference plasmid Renilla luciferase and the IC 50 value.
[0075] Table 2. IC of SHD Fr inhibitory effects on different targets 50 value
[0076]
[0077] The results are shown in Table 2. SHD Fr has a strong inhibitory effect on TNF-α and JAK1. 50 The values were 1.45 μg / mL and 0.58 μg / mL, respectively, while for other targets, the IC 50 The values were all greater than 200 μg / mL, indicating that SHD Fr exerts anti-RA activity by inhibiting TNF-α and JAK1. This shows that Taoerqi exerts anti-RA activity by inhibiting the "dual targets" TNF-α and JAK1.
[0078] Effects of SHD Fr on TNF-α and JAK1 downstream signaling pathways
[0079] Nuclear factor of activated T cells 1 (NFATc1) is crucial in RA disease. TNF-α and JAK1 in synovial tissue can regulate NFATc1 expression through different signal transduction pathways, thereby causing the occurrence and development of RA disease. After TNF-α binds to TNFR1, it causes TRADD to bind to TNFR1, recruits RIP-1 and TRAF2 / 4 / 5, and further activates NF-κB, JNK and p38 signal transduction, prompting the effective activation of NFATc1. On the other hand, PLC-γ activated by JAK1 will also cause an increase in calcium concentration and increase calcinurin expression, thereby causing an increase in NFATc1.
[0080] The rat RA model induced by complete Freund's adjuvant (CFA) was used to evaluate the effect of SHD Fr on TNF-α and JAK1 downstream signaling pathways. The model establishment, experimental grouping and administration scheme were the same as those in Example 3.
[0081] The rat synovial tissue was separated and cut into small pieces. The lysate was added to obtain the total protein. The total protein content was determined by BCA kit. The sample protein was denatured. Constant voltage SDS-PAGE electrophoresis was performed and the protein was transferred to PVDF membrane at constant current. 5% skim milk powder was blocked and primary antibodies (1:1000) such as RIP-1, TRAF2, TRAF4, TRAF5, AP-1, c-fos, p38, JNK, PLC and internal reference were added respectively. The membrane was incubated overnight at 4°C. The membrane was washed three times with TBST and incubated with HRP-labeled secondary antibody (1:10000). The membrane was washed with TBST and chemiluminescence was detected. The protein content was analyzed by density using Image J image analysis software.
[0082] The rat synovial tissue was removed and immediately placed in 4% paraformaldehyde (PFA) fixative at 4°C for 4-6 hours. After fixation, it was dehydrated with gradient ethanol, then embedded in paraffin, and the tissue was cut into 5μm thick slices using a slicer and attached to a slide. Blocked with 5% bovine serum albumin in PBS at room temperature for 30 minutes to block nonspecific binding. The primary antibodies against NFATc1 and NF-κB were added to the slices at an appropriate dilution ratio (1:200) and incubated overnight at 4°C. The slices were washed with PBS 3 times, 5 minutes each time. Secondary antibodies with different fluorescent labels (Alexa Fluor 488-labeled anti-NFATc1 secondary antibody and AlexaFluor 594-labeled anti-NF-κB secondary antibody, diluted according to the instructions) were added and incubated at room temperature in the dark for 1 hour. The slices were washed with PBS 3 times, 5 minutes each time. DAPI solution (or other nuclear dyes) were added and incubated in the dark for 5-10 minutes. The slices were sealed with anti-fluorescence quenching sealing agent and covered with a coverslip. Observe and photograph under a fluorescence microscope.
[0083] Western-blot and immunofluorescence results are shown in Figure 5 As shown, SHD Fr can inhibit the expression of RIP-1, TRAF2, TRAF4, and TRAF5 in the synovial tissue of RA rats, inhibit NF-κB nuclear translocation, and inhibit JNK and p38 phosphorylation. In addition, SHDFr can also inhibit PLC-γ phosphorylation in the synovial tissue of RA rats, inhibit Calcinurin expression, reduce calcium ion concentration, and ultimately reduce NFATc1. The above results show that SHD Fr has an effect on the downstream signaling pathways of TNF-α and JAK1, further verifying the prediction results of network pharmacology targets.
[0084]
[0085]
[0086]
[0087]
[0088]
Claims
1. An effective part of Psoralea corylifolia, characterized in that: It is the dichloromethane extraction part of the alcohol extract of the rhizome of Psoralea corylifolia.
2. The effective part of Psoralea corylifolia according to claim 1, characterized in that: The alcohol extract of the rhizome of Psoralea corylifolia is prepared by taking the dried rhizome of Psoralea corylifolia as raw material, taking 75% to 95% ethanol as extraction solvent, performing reflux extraction and filtering to obtain an extract, and recovering the extract until there is no alcohol taste to obtain an extract.
3. The effective part of Psoralea corylifolia according to claim 1, characterized in that: The method uses dried rhizome of Prunus persica as raw material, uses 75% to 95% ethanol as extraction solvent, performs reflux extraction and filtering to obtain an extract, recovers the extract until it has no alcohol taste to obtain an extract, suspends the extract in water, first extracts with petroleum ether, then extracts with dichloromethane, and concentrates the dichloromethane extract to dryness to obtain a dichloromethane extraction fraction.
4. The effective part of Psoralea corylifolia according to claim 3, characterized in that: The effective part of Psoralea corylifolia is prepared by the following method: using dried Psoralea corylifolia rhizome as raw material, crushing, adding 75% to 95% ethanol at a solid-liquid ratio of 1:10kg / L for reflux extraction, adding 75% to 95% ethanol at a solid-liquid ratio of 1:8kg / L for reflux extraction twice for the filter residue; after each reflux extraction, filtering, collecting the extract, and combining the extracts; The extract is recovered until there is no alcohol taste to obtain an extract, the extract is suspended in water, extracted with petroleum ether for 3 times, and extracted with dichloromethane for 3 times in sequence, and the dichloromethane extract is concentrated to dryness to obtain the dichloromethane extraction part, which is the effective part of Psoralea corylifolia.
5. The effective part of Psoralea corylifolia according to claim 2, 3 or 4, characterized in that: The extraction solvent is 95% ethanol; the time of each reflux extraction is 1 hour.
6. Use of the effective fraction of Psoralea corylifolia as described in any one of claims 1 to 4 in the preparation of a drug for treating rheumatoid arthritis.
7. The use according to claim 6, characterized in that: The application is the application of the effective part of Psoralea corylifolia in preparing a drug for treating rheumatoid arthritis by inhibiting TNF-α and JAK1.
8. A drug for treating rheumatoid arthritis, characterized in that: Contains an effective therapeutic dose of the effective part of Psoralea corylifolia as described in any one of claims 1 to 4, and pharmaceutically acceptable excipients.
9. The drug according to claim 8, characterized in that: The medicine is an oral preparation.
10. The drug according to claim 9, characterized in that: The oral preparations are tablets, capsules, granules, suspensions, dripping pills, pills, and oral liquid preparations.
Citation Information
Patent Citations
Method for preparing high-purity podophyllotoxin from Chinese podophyllum root
CN101503410A
Preparation method and application of isopentene alkenylation flavonoid compound with nerve protection effect
CN105198854A
